Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glargine-based Discharge Algorithm in Cardiac Surgery
NCT01792830Phase 3Completed
- Sponsor
- Emory University
- Start
- Oct 2012
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of insulin glargine in hyperglycemia and type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Emory University. Primary endpoint: Change in HbA1c Levels at 12 weeks. Started Oct 2012; status: completed.
02
Drugs
insulin glargine
03
Conditions
hyperglycemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01792830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01792830.